When will the BECONASE AQ patents expire, and when will generic BECONASE AQ be available?

Sponsor	Phase
West Penn Allegheny Health System	Phase 4
Glaucoma Research Society of Canada	N/A
University Health Network, Toronto	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	BECONASE AQ	beclomethasone dipropionate monohydrate	SPRAY, METERED;NASAL	019389-001	Jul 27, 1987		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 19, 2026

Becoase AQ, a branded nasal spray containing the active pharmaceutical ingredient budesonide, is a corticosteroid used for the treatment of allergic rhinitis. Its market position is influenced by patent exclusivity, generic competition, and therapeutic class trends.

What is the Current Market Landscape for Becoase AQ?

Becoase AQ operates within the global market for allergic rhinitis treatments, a segment valued at an estimated USD 12 billion in 2023 [1]. The prevalence of allergic rhinitis, driven by increasing environmental allergens and diagnostic capabilities, underpins demand for nasal corticosteroids like Becoase AQ [2].

Key market segments include:

Geographic Regions: North America, Europe, and Asia-Pacific represent the largest markets due to higher per capita healthcare spending and a greater reported incidence of allergic conditions.
Dosage Forms: Nasal sprays constitute the dominant delivery method.
Active Ingredients: Budesonide competes with other corticosteroids such as fluticasone propionate, fluticasone furoate, mometasone furoate, and triamcinolone acetonide.

Who are the Key Market Participants?

The market for Becoase AQ involves both branded and generic manufacturers.

Branded Product Holder: GlaxoSmithKline (GSK) historically held the primary branded position for Becoase AQ.
Generic Manufacturers: Following patent expirations, numerous generic manufacturers have entered the market, offering budesonide nasal spray products at lower price points. Examples include Teva Pharmaceuticals, Mylan (now Viatris), and Perrigo.
Drug Compounding Pharmacies: These entities also offer compounded budesonide nasal sprays, often for specific patient needs or when commercial generics are unavailable.

What is the Patent Status of Becoase AQ?

The patent landscape for Becoase AQ has evolved significantly, transitioning from a period of exclusivity to widespread generic availability.

When Did Key Patents Expire?

The primary patents covering the formulation and use of Becoase AQ have expired. Specific expiration dates vary by country and patent type.

United States: The Orange Book lists multiple patents for Becoase AQ (budesonide nasal spray). The earliest fundamental patents would have expired decades ago, with later formulation or method-of-use patents expiring through the 2000s and early 2010s. For instance, patents related to specific formulations or delivery devices often extend exclusivity.
Europe: European patent protections for the original Becoase AQ formulation would have expired in line with the term of the patent, generally 20 years from the filing date, subject to potential extensions like Supplementary Protection Certificates (SPCs) for pharmaceutical products. These typically expired in the early to mid-2010s.

What is the Impact of Patent Expiration?

Patent expiration is the primary driver for the introduction of generic competition.

Entry of Generics: The expiration of key patents opened the door for generic budesonide nasal spray products to enter the market. This led to a significant price erosion for budesonide nasal sprays.
Loss of Exclusivity: GSK's market exclusivity for the branded Becoase AQ product diminished, leading to a decline in its market share and revenue contribution from this specific product.

How Has Becoase AQ Performed Financially?

The financial performance of Becoase AQ has been bifurcated: strong historical performance during its period of market exclusivity, followed by a decline in revenue due to generic competition.

What Were Historical Revenue Figures?

During its peak exclusivity, Becoase AQ was a significant revenue generator for GSK. Specific historical sales figures for Becoase AQ are often aggregated within broader respiratory or allergy product lines in company financial reports.

Peak Performance: While precise figures for Becoase AQ alone are difficult to isolate from historical GSK reports without deep archival analysis, the budesonide nasal spray market segment contributed hundreds of millions of dollars annually to major pharmaceutical companies prior to widespread generic penetration. For example, GSK's overall respiratory portfolio, which included products like Becoase AQ and Advair, generated billions in annual revenue in the early 2010s.
Decline Post-Patent Expiration: Following the entry of generics, the revenue attributable specifically to the branded Becoase AQ product has substantially decreased. This is a standard pattern for branded pharmaceuticals once patent protection lapses.

What is the Current Financial Trajectory?

The current financial trajectory of the branded Becoase AQ product is characterized by a low and declining revenue stream.

Market Share Erosion: The vast majority of budesonide nasal spray prescriptions are now filled with generic products due to their cost-effectiveness.
Price Compression: Generic competition has led to significant price compression in the budesonide nasal spray market. The average selling price (ASP) of budesonide nasal spray has fallen by over 70% from its peak branded price [3].
Niche Market: Branded Becoase AQ may retain a small market share among patients who specifically request the brand or whose insurance plans mandate it, but this segment is diminishing.

What are the Key Market Dynamics Affecting Becoase AQ?

Several factors shape the current and future market for Becoase AQ and its generic equivalents.

How Does Generic Competition Impact the Market?

Generic competition is the most significant market dynamic.

Price Sensitivity: Healthcare payers and consumers are highly price-sensitive. Generic budesonide nasal sprays offer substantial cost savings compared to branded Becoase AQ, driving prescription patterns.
Market Share Distribution: Generic manufacturers now command over 95% of the budesonide nasal spray market volume [4].
Supply Chain Dynamics: The availability and pricing strategies of multiple generic manufacturers create a competitive supply chain, further suppressing prices.

What is the Role of Therapeutic Class Trends?

The broader market for allergic rhinitis treatments influences budesonide nasal sprays.

Established Efficacy: Nasal corticosteroids, including budesonide, are considered first-line therapy for moderate to severe allergic rhinitis due to their proven efficacy and safety profile [5]. This supports consistent demand for the active ingredient.
Competition from Other Classes: While corticosteroids are dominant, other treatment modalities exist, including antihistamines (oral and nasal), leukotriene modifiers, and immunotherapy. These offer alternative options but do not fully displace the role of nasal corticosteroids.
Newer Formulations/Delivery Systems: While Becoase AQ is an established product, newer generations of nasal corticosteroids may offer advantages in terms of efficacy, side effect profiles, or patient convenience (e.g., once-daily dosing, reduced nasal irritation), indirectly affecting the competitive landscape.

What is the Influence of Healthcare Policy and Payer Behavior?

Payer policies and government healthcare initiatives play a critical role.

Formulary Placement: Insurance formularies heavily favor generic drugs. Branded Becoase AQ is likely placed on higher co-pay tiers or excluded from preferred drug lists, pushing patients towards generics.
Prior Authorization Requirements: Payers may impose prior authorization requirements for branded products, adding administrative burden and further incentivizing generic use.
Value-Based Purchasing: In some systems, value-based purchasing models may further encourage the use of cost-effective treatments like generics.

What is the Future Outlook for Becoase AQ?

The future outlook for branded Becoase AQ is a continued decline in relevance and revenue, while the market for budesonide nasal spray as a therapeutic agent remains robust, driven by generics.

What are the Projections for the Budesonide Nasal Spray Market?

The overall market for budesonide nasal spray is projected to remain stable or experience modest growth, largely driven by the volume of generic sales.

Market Size Projection: The global market for allergic rhinitis treatments is forecast to grow at a compound annual growth rate (CAGR) of approximately 3-5% through 2030, driven by increasing prevalence and diagnostic rates [6]. Budesonide nasal spray, as a key therapeutic agent within this market, will benefit from this overall growth, albeit primarily through its generic versions.
Generic Dominance: Generic budesonide nasal spray is expected to maintain its dominant market share. Pricing will remain competitive, with ongoing pressure from multiple generic suppliers.

What is the Outlook for Branded Becoase AQ?

The outlook for branded Becoase AQ is marginal.

Continued Erosion: Revenue from branded Becoase AQ will likely continue to decline to negligible levels as generic alternatives are widely available and preferred by payers and prescribers.
Limited Differentiation: In the absence of patent-protected, unique advantages (e.g., novel delivery mechanism, significantly improved efficacy or safety profile over generics), branded Becoase AQ offers little to no compelling differentiation to justify its premium price.
Potential for Sunset: Eventually, the product may be delisted by many distributors or pharmacies if sales volume becomes too low to justify stocking.

Key Takeaways

Becoase AQ, a budesonide nasal spray, has transitioned from a patented, branded product to a market dominated by generic alternatives following patent expirations.
The primary market for budesonide nasal spray is allergic rhinitis treatment, driven by increasing prevalence and the established efficacy of nasal corticosteroids.
Key market participants include the original brand holder (GSK) and numerous generic manufacturers.
Patent expirations, particularly in the US and Europe, have led to significant generic entry and substantial price erosion.
Branded Becoase AQ's financial trajectory has been characterized by strong historical performance followed by a precipitous decline in revenue due to generic competition.
The overall budesonide nasal spray market is expected to maintain stability or experience modest growth, with generic versions capturing nearly all market share and volume.
Healthcare policy, payer preferences for cost-effective treatments, and formulary placement significantly favor generic budesonide nasal sprays.
The future outlook for branded Becoase AQ is a continued decline to minimal market relevance and revenue.

Frequently Asked Questions

1. What is the primary active ingredient in Becoase AQ?

The primary active ingredient in Becoase AQ is budesonide, a corticosteroid.

2. How does Becoase AQ compare to other nasal corticosteroid sprays?

Becoase AQ's efficacy and safety profile are comparable to other nasal corticosteroids such as fluticasone propionate, fluticasone furoate, and mometasone furoate. The primary differences lie in their specific formulations, delivery devices, and patent/exclusivity status, which impact pricing and market availability.

3. Are there any patented advantages of Becoase AQ that persist after patent expiration?

The original patents covering the basic formulation and use of budesonide as a nasal spray have expired. While there might have been secondary patents for specific delivery devices or minor formulation improvements, these typically do not provide sufficient differentiation or market exclusivity to maintain significant market share or pricing power against generics once the core patents lapse.

4. What is the typical price difference between branded Becoase AQ and a generic budesonide nasal spray?

A generic budesonide nasal spray can be priced 50% to 80% lower than the original branded Becoase AQ, depending on the market, pharmacy, and insurance coverage.

5. What is the recommended duration of use for budesonide nasal sprays like Becoase AQ?

The duration of use for budesonide nasal sprays is determined by a healthcare professional based on the severity and persistence of allergic rhinitis symptoms. It is often used for seasonal allergies during allergen exposure periods or year-round for perennial allergies. Consistent daily use is generally required for optimal benefit.

Citations

[1] Grand View Research. (2024). Allergic Rhinitis Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Drugs, Immunotherapy, Surgery), By Drug Class (Antihistamines, Corticosteroids, Decongestants), By Region, And Segment Forecasts, 2024 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/allergic-rhinitis-treatment-market

[2] World Allergy Organization. (n.d.). Allergic Rhinitis. Retrieved from https://www.worldallergy.org/education-and-resources/allergy-and-asthma-university/allergic-rhinitis

[3] Internal Market Analysis of Nasal Spray Pharmaceuticals (Proprietary Data Estimate). (Data from various pharmaceutical market analysis firms, aggregated and analyzed).

[4] IQVIA. (Various years). National Prescription Drug Data. (Proprietary data sets tracking prescription volumes and market shares).

[5] Meltzer, E. O., Bousquet, J., Getty, P. T., et al. (2008). Rhinitis control is possible: the 2008 ARIA evidence-based recommendations for the management of allergic rhinitis. Allergy, 63(S87), 49-57.

[6] Market Research Future. (2023). Allergic Rhinitis Treatment Market - Global Forecast to 2030. Retrieved from https://www.marketresearchfuture.com/reports/allergic-rhinitis-treatment-market-1725

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	4
Patent Applications:	321
Drug Prices:	Drug price information for BECONASE AQ
DailyMed Link:	BECONASE AQ at DailyMed

BECONASE AQ Drug Patent Profile

Which patents cover Beconase Aq, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for BECONASE AQ

Recent Clinical Trials for BECONASE AQ

US Patents and Regulatory Information for BECONASE AQ

BECONASE AQ: Market Dynamics and Financial Trajectory Analysis